tradingkey.logo

Bio Rad Laboratories Inc

BIOb
309.655USD
+7.315+2.42%
收盘 02/09, 16:00美东报价延迟15分钟
8.75B总市值
亏损市盈率 TTM

Bio Rad Laboratories Inc

309.655
+7.315+2.42%

关于 Bio Rad Laboratories Inc 公司

Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.

Bio Rad Laboratories Inc简介

公司代码BIOb
公司名称Bio Rad Laboratories Inc
上市日期Mar 17, 1980
CEOSchwartz (Norman D)
员工数量7700
证券类型Ordinary Share
年结日Mar 17
公司地址1000 Alfred Nobel Dr
城市HERCULES
上市交易所NASDAQ OMX NASDAQ Basic NYSE
国家United States of America
邮编94547
电话15107247000
网址https://www.bio-rad.com/
公司代码BIOb
上市日期Mar 17, 1980
CEOSchwartz (Norman D)

Bio Rad Laboratories Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Norman D. Schwartz
Mr. Norman D. Schwartz
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
431.47K
+57000.00%
Mr. James J. Barry
Mr. James J. Barry
Executive Vice President, President - Life Science Group
Executive Vice President, President - Life Science Group
--
--
Ms. Eva Anette Engelhardt
Ms. Eva Anette Engelhardt
Executive Vice President, President of Clinical Diagnostics Group
Executive Vice President, President of Clinical Diagnostics Group
--
--
Mr. Jonathan P. (Jon) Divincenzo
Mr. Jonathan P. (Jon) Divincenzo
President, Chief Operating Officer
President, Chief Operating Officer
--
--
Ms. Courtney C Enloe
Ms. Courtney C Enloe
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
--
--
Rajat Mehta
Rajat Mehta
Executive Vice President - Global Commercial Operations
Executive Vice President - Global Commercial Operations
--
--
Mr. Jeffrey L. (Jeff) Edwards
Mr. Jeffrey L. (Jeff) Edwards
Independent Director
Independent Director
--
--
Mr. Gregory K. (Greg) Hinckley, CPA
Mr. Gregory K. (Greg) Hinckley, CPA
Lead Independent Director
Lead Independent Director
--
--
Ms. Melinda Litherland
Ms. Melinda Litherland
Independent Director
Independent Director
--
--
Mr. Arnold A. Pinkston
Mr. Arnold A. Pinkston
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Norman D. Schwartz
Mr. Norman D. Schwartz
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
431.47K
+57000.00%
Mr. James J. Barry
Mr. James J. Barry
Executive Vice President, President - Life Science Group
Executive Vice President, President - Life Science Group
--
--
Ms. Eva Anette Engelhardt
Ms. Eva Anette Engelhardt
Executive Vice President, President of Clinical Diagnostics Group
Executive Vice President, President of Clinical Diagnostics Group
--
--
Mr. Jonathan P. (Jon) Divincenzo
Mr. Jonathan P. (Jon) Divincenzo
President, Chief Operating Officer
President, Chief Operating Officer
--
--
Ms. Courtney C Enloe
Ms. Courtney C Enloe
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
--
--
Rajat Mehta
Rajat Mehta
Executive Vice President - Global Commercial Operations
Executive Vice President - Global Commercial Operations
--
--

收入明细

单位: USD更新时间: 1月6日 周二
单位: USD更新时间: 1月6日 周二
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
由于公司未披露,未能获取相关数据
地区USD
名称
营收
占比
United States
270.00M
41.35%
EMEA
222.20M
34.03%
APAC
121.00M
18.53%
Other
39.80M
6.09%
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 4月2日 周三
更新时间: 4月2日 周三
持股股东
股东类型
持股股东
持股股东
占比
Blue Raven Partners, L.P.
80.10%
Alice N. Schwartz Revocable Trust
8.63%
Schwartz (Norman D)
8.51%
Schwartz (Steven D)
0.75%
Allison (Schwartz)
0.08%
其他
1.92%
持股股东
持股股东
占比
Blue Raven Partners, L.P.
80.10%
Alice N. Schwartz Revocable Trust
8.63%
Schwartz (Norman D)
8.51%
Schwartz (Steven D)
0.75%
Allison (Schwartz)
0.08%
其他
1.92%
股东类型
持股股东
占比
Corporation
88.74%
Individual Investor
9.35%
Investment Advisor
0.07%
其他
1.85%

机构持股

更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
13
3.81K
0.08%
+600.00
2025Q3
15
3.80K
0.10%
+757.00
2025Q2
15
3.05K
0.12%
+2.00
2025Q1
18
3.04K
0.13%
-3.56K
2024Q4
18
4.22K
0.13%
-23.00
2024Q3
17
4.24K
0.12%
+647.00
2024Q2
18
3.60K
0.13%
-211.00
2024Q1
19
3.81K
0.15%
-3.64K
2023Q4
20
3.78K
2.06%
-1.99K
2023Q3
20
5.76K
2.06%
+2.00
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Blue Raven Partners, L.P.
4.06M
80.1%
--
--
Sep 25, 2025
Alice N. Schwartz Revocable Trust
437.51K
8.63%
--
--
Sep 25, 2025
Schwartz (Norman D)
431.47K
8.51%
+57.00K
+15.22%
Sep 25, 2025
Schwartz (Steven D)
38.24K
0.75%
--
--
Sep 25, 2025
Allison (Schwartz)
4.00K
0.08%
+57.00
+1.45%
Feb 24, 2025
CSS, LLC
1.09K
0.02%
--
--
Sep 30, 2025
Focus Partners Wealth, LLC
760.00
0.01%
+760.00
--
Sep 30, 2025
Buckingham Strategic Wealth, LLC
760.00
0.01%
--
--
Jun 30, 2024
Morgan Stanley Smith Barney LLC
692.00
0.01%
--
--
Sep 30, 2025
Wells Fargo Advisors
170.00
0%
--
--
Sep 30, 2025
查看更多

持股ETF

机构名称
占比
暂无数据

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
除权除息日
类型
比率
暂无数据
公告日期
除权除息日
类型
比率
暂无数据
KeyAI